Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2004 May 4; 90(9): 1780–1783.
Published online 2004 Mar 23. doi:  10.1038/sj.bjc.6601744
PMCID: PMC2409759

Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s

Mammographic screening has been shown to reduce breast cancer mortality rates (Vainio and Bianchini, 2002). Several studies in northern European countries (Hermon and Beral, 1996; Hakama et al, 1997; Van den Akker-van Marle et al, 1999; Blanks et al, 2000; Jonsson et al, 2001; Botha et al, 2003; Otto et al, 2003; Tabar et al, 2003) have reported a decrease in breast cancer mortality where nationwide screening programmes have been implemented. There has, however, been considerable debate concerning the relative contributions of screening and of improved therapy to the observed trends (Carnon et al, 1996; Blanks et al, 2000; Peto et al, 2000).

At the beginning of the 1970s in 23 rural municipalities of the province of Florence, Italy (early screening area (ES area) among about 70 000 resident women aged 25 or over, 18% of women of the province, based on 1991 Census), a mammographic screening programme was started; until 1989, women in the 40–69 year age group were invited, whereas from that year onwards the target population was restricted to age group 50–69 years. The number of mammograms performed in the ES area was 8000–9000 per year. The efficacy of the programme on breast cancer mortality in the ES area has been evaluated for the period 1977–1984 by means of case–control studies (Palli et al, 1986, 1989), and by using early indicators of efficacy (Paci et al, 1990). After 1990, when the screening for women aged 50–69 years started in the rest of the province, including the city of Florence (late screening area: LS area), the number of mammograms in the whole province increased to 28 000–29 000 per year (Barchielli et al, 1999).

In this study, we have compared breast cancer mortality rates in the period 1985–2000 in the ES and LS areas.


Sources of data

Data on breast cancer mortality for the period 1985–2000 were obtained from the Tuscan Regional Mortality Register (Chellini et al, 2002), which collects death certificates of the residents of Tuscany. Incident breast cancer cases for the period 1985–1999 were obtained from the Tuscan Cancer Register, a member of the International Association of Cancer Registries (Parkin et al, 2002).

Statistical analysis

Adjusted mortality and incidence rates using direct standardisation to the European Standard Population, and age-specific (35–44, 45–54, 55–64, 65–74, 75–84 and ⩾85 years) incidence and mortality rates with 95% confidence intervals (95% CI) were calculated.

In order to calculate the estimated percent change (EPC) in rates for the whole period of observation, trends in mortality and incidence based on annual data were examined using a log-linear regression model, and the year of death as a continuous variable.


The age-adjusted mortality rate in the ES area (Figure 1) was 22.4 per 100 000 women in 1985 (95% CI: 13.6–31.2; 27 deaths), 31.8 in 1991 (95% CI: 21.0–42.6; 38 deaths) and then decreased to 10.9 in 2000 (95% CI: 5.4–16.5; 19 deaths). In the LS area, the corresponding age-standardised mortality rates were more stable with only a slight decrease over time: in 1985 30.1 per 100 000 women (95% CI: 25.5–34.7; 186 deaths); 27.7 in 2000 (95% CI: 23.3–32.1; 190 deaths). In the ES area, age-specific mortality rates decreased steadily from 1985 to 1986 until 1999–2000 in all age groups, except for 85+ age group (Figure 2). The age-specific rates in the LS area were more stable (Figure 3).

Figure 1
Age-adjusted (European population) breast cancer mortality rates in the ES area and in the LS area. Period 1985–2000, 3-year moving averages.
Figure 2
Age-specific mortality rates in the period 1985–2000 in the ES area of the province of Florence, Italy.
Figure 3
Age-specific mortality rates in the period 1985–2000 in the LS area of the province of Florence, Italy.

In the ES area, incidence was 76.9 per 100 000 women in 1985 (95% CI: 59.6–94.1), 96.7 in 1989 (95% CI: 77.6–115.8), 62.5 in 1993 (95% CI: 47.9–77.1) and 110.6 in 1999 (95% CI: 90.8–130.4). In the LS area, incidence rates were higher: 91.1 per 100 000 women in 1985 (95% CI: 82.6–99.6), 112.1 in 1993 (95% CI: 102.9–121.4) and 113.9 in 1999 (95% CI: 104.5–123.4).

In addition to visual inspection, we measured EPCs in rates over the whole period (Table 1 ). In the period 1985–2000, the overall age-standardised mortality decreased by 40.9% in the ES area (P<0.001), and by 11.3% in the LS area (P=0.030). Significant decreases in the ES area were detected in age groups 45–54 years (61.1%; P=0.018) and 65–74 years (44.7%; P=0.049). In the 75–84 age group, the decrement was 45.2% (P=0.053). In the LS area, no significant decreases were detected in any age group.

Table 1
Estimated percentage change (EPC) and 95% confidence intervals (95% CI) of mortality rates (1985–2000) and incidence rates (1985–1999) in Early Screening area and in Late Screening area

In the period 1985–1999, the overall age-standardised incidence increased by 12.9% in the ES area (P=0.190), and by 14.2% in the LS area (P<0.001) (Table 1). In the ES area, no significant increases or decreases were detected in any age groups; in the LS area, where the prevalence screening was carried out in the period 1990–1994, significant increases were detected in groups aged 55–64 years (21.0%; P=0.009) and 85 years and over (45.1%; P=0.012).


Decreases in breast cancer mortality have been variously reported following the introduction of mammographic screening on a regional level (Tornberg et al, 1994; Quinn and Allen, 1995; Garne et al, 1997; Barchielli and Paci, 2001; Broeders et al, 2001; Tabar et al, 2001; Duffy et al, 2002). Randomised prospective trials indicate that benefits in terms of cumulative breast cancer mortality start to emerge 4–10 years after randomisation (Nyström et al, 2002). We observed a similar trend in the mortality rates in the two areas up to 1993, although the mortality rates in the ES area were lower than those in the LS area. Afterwards a marked fall occurred in ES area, whereas only a slight decrease was observed in the LS area. The relatively low compliance in the first years of the programme in both areas (about 55%) and the long enrolment period (on average 2.5 years) in the LS area (Paci et al, 2002a, 2002b) could have diluted the effect so that a decrease in mortality rates was observed only after a longer interval.

Our findings suggest that the drop in mortality in the ES area (41%) could be explained by both service screening and better care. The slight decrease in mortality in the LS area (11%) could be explained by better care, while service screening of the period 1990–2000 in the LS area could have been responsible for only a small number of deaths occurring in the target population. In fact, it has been estimated that in the city of Florence, the breast cancer mortality reduction at ages 50–74 years attributable to screening was 3.2% over the period 1990–1999 (Paci et al, 2002a). Thus, allowing a 11% reduction due to better care, a reduction of about 30% (41–11%) is attributable to screening in the ES area over the period 1985–2000. These findings are consistent with the mortality reduction of about 25% in screened populations shown by randomised trials (Vainio and Bianchini, 2002).

The decrease in mortality at ages 45–54 years in the ES area could be related to the involvement in mammographic screening of women aged 40–49 years in the ES area until 1993. In 1985–1993, 33% of mammograms in the ES area (about 2700 per year) were performed on women aged 40–49 years. No mortality reduction would be expected from screening in the younger age group (35–44 years) or in the 85 years and over age group.

In evaluating these results, it must be borne in mind that the ES area, where the incidence rates were lower, was a less urbanised area during the period of observation. The significant increase in incidence recorded only in the LS area (of 14.2%), particularly in women aged 55–64 years (21.0%), could be explained by earlier detection. Increases in incidence have been recorded in other Western countries in relation to screening (Quinn and Allen, 1995; Garne et al, 1997; Persson et al, 1998; Chu et al, 1996; Rostgaard et al, 2001). In the ES area, no significant increase in incidence was detected. It is likely that an increase in incidence in the ES area should have occurred in the 1970s, as a result of screening.

Incidence trends in the ES and LS areas do not seem to explain the observed differences in mortality rates during the study period. The present results seem to confirm that service screening can reduce breast cancer mortality rates.


We thank Andrea Martini and Paola Piccini for statistical assistance, and Vanessa Bolejack for proofreading.


  • Barchielli A, Paci E, Giorgi D. Recent trends of in situ carcinoma of the breast and mammographic screening. Cancer Causes Control. 1999;10:313–317. [PubMed]
  • Barchielli A, Paci E. Trends in breast cancer mortality, incidence, and survival and mammographic screening in Tuscany, Italy. Cancer Causes Control. 2001;12:249–255. [PubMed]
  • Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990–8: comparison of observed with predicted mortality. BMJ. 2000;321:665–669. [PMC free article] [PubMed]
  • Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39:1718–1729. [PubMed]
  • Broeders MJ, Peer PG, Straatman H, Beex LV, Hendriks JH, Holland R, Verbeek AL. Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and the Netherlands, 1969–97. Int J Cancer. 2001;92:303–308. [PubMed]
  • Carnon A, Hole D, Gillis C, Brewster D. Incidence of and mortality from breast cancer since introduction of screening. Several factors must have a role in improved figures. BMJ. 1996;312:640. [PMC free article] [PubMed]
  • Chellini E, Giovannetti L, Gorini G, Sorso B, Fornai MG, Martini A, Lisi C, Querci A. Morti per causa anno 2000. Registro Mortalità Regionale. Firenze: Regione Toscana; 2002.
  • Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, Edwards BK. Recent trends in U.S. breast cancer incidence, survival and mortality rates. J Natl Cancer Inst. 1996;88:1571–1579. [PubMed]
  • Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M, Wiege M, Akerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosen M, Stenbeck M, Holmberg L. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer. 2002;95:458–469. [PubMed]
  • Garne J, Aspergren K, Balldin G, Ranstam J. Increasing incidence of and declining mortality from breast carcinoma. Trends in Malmo, Sweden. Cancer. 1997;79:69–74. [PubMed]
  • Hakama M, Pukkala E, Heikkilä M, Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997;314:864–867. [PMC free article] [PubMed]
  • Hermon G, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western citites: analysis of time trends, age–cohort and age–period models of breast cancer mortality in 20 countries. Br J Cancer. 1996;73:955–960. [PMC free article] [PubMed]
  • Jonsson H, Nystrom L, Tornberg S, Lenner P. Service screening with mammography of women aged 50–69 years in Sweden: effects on mortality from breast cancer. J Med Screen. 2001;8:152–160. [PubMed]
  • Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359:909–919. [PubMed]
  • Otto SJ, Fracheboud J, Looman CWN, Broeders MJM, Boer R, Hendriks JHCL, Verbeek ALM, de Konig HJ, and the National Team for Breast Cancer Screening Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361:1411–1417. [PubMed]
  • Paci E, Ciatto S, Buiatti E, Cecchini S, Palli D, Rosselli del Turco M. Early indicators of efficacy of breast cancer screening programmes. Results of the Florence District Programme. Int J Cancer. 1990;46:198–202. [PubMed]
  • Paci E, Giorgi S, Bianchi S, Vezzosi V, Zappa M, Crocetti E, Rosselli del Turco M. Assessment of the early impact of the population-based breast cancer screening in Florence (Italy) using mortality and surrogate measures. Eur J Cancer. 2002a;38:568–573. [PubMed]
  • Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, Bianchi S, Rosselli E, Rosselli del Turco M. Quantification of the effect of mammographic screening on fatal breast cancers: the Florence Programme 1990–96. Br J Cancer. 2002b;87:65–69. [PMC free article] [PubMed]
  • Palli D, Del Turco MR, Buiatti E, Carli S, Ciatto S, Toscani L, Maltoni G. A case–control study of the efficacy of a non-randomized breast cancer screening program in Florence (Italy) Int J Cancer. 1986;38:501–504. [PubMed]
  • Palli D, Rosselli del Turco M, Buiatti E, Ciatto S, Crocetti E, Paci E. Time interval since last test in a breast cancer screening programme: a case–control study in Italy. J Epidemiol Commun Health. 1989;43:241–248. [PMC free article] [PubMed]
  • Parkin D, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents 2002Lyon, France: International Agency for Research on Cancer, World Heath Organization; Vol. VIII, IARC Scientific Publication No. 155
  • Persson J, Bergstrom R, Barlow L, Adami HO. Recent trends in breast cancer incidence in Sweden. Br J Cancer. 1998;77:167–169. [PMC free article] [PubMed]
  • Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355:1822. [PubMed]
  • Quinn M, Allen E. Changes in incidence and mortality from breast cancer in England and Wales since introduction of screening. BMJ. 1995;311:1391–1395. [PMC free article] [PubMed]
  • Rostgaard K, Vaeth M, Holst H, Madsen M, Lhynge E. Age–period-cohort modeling for breast cancer incidence in the Nordic countries. Stat Med. 2001;20:47–61. [PubMed]
  • Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized clinical trials: organized mammographic screening substantially reduces breast cancer mortality. Cancer. 2001;91:1724–1731. [PubMed]
  • Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after the introduction of screening. Lancet. 2003;361:1405–1410. [PubMed]
  • Tornberg S, Carstersen J, Hakyulinen T, Lenner P, Hatschek T, Lundgren B. Evaluation of the effect on breast cancer mortality of population-based mammography screening programmes. J Med Screen. 1994;1:184–187. [PubMed]
  • Vainio H, Bianchini F. Breast Cancer Screening 2002Lyon, France: International Agency for Research on Cancer, World Heath Organization; IARC Handbooks of Cancer Prevention, Vol. 7
  • Van den Akker-van Marle E, de Koning H, Boer R, van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom. J Med Screen. 1999;6:30–34. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...